H.C. Wainwright analyst Robert Burns raised the firm’s price target on Cardiff Oncology (CRDF) to $18 from $17 and keeps a Buy rating on the shares following the Q1 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRDF:
- Cardiff Oncology’s Strategic Advances in Cancer Treatment: A Compelling Buy Opportunity
- Promising Clinical Trial Developments Drive Buy Rating for Cardiff Oncology
- Cardiff Oncology reports Q1 EPS (20c), consensus (19c)
- Promising Developments in Cardiff Oncology’s Cancer Treatment Boost Buy Rating
- CRDF Earnings this Week: How Will it Perform?